Latest Kidney Cancer News
Kidney Cancer News elsewhere on the Web
Current guidelines on treatment of metastatic renal cell carcinoma (mRCC) suggest an emerging role of local therapy (LT). Still there is a lack of data which patients may benefit from additional LT once medical treatment (MT) is initiated. We retrospectively aim to characterize LT in patients ...
Combining renal vaccines with immune therapy may better target tumor cells while limiting harm to healthy tissue, according to David A. Braun, MD, PhD.
KIM-1 is a biomarker in the blood that may help noninvasively detect kidney cancer, according to Wenxin (Vincent) Xu, MD.
Alan Tan, MD, discusses how a trial analysis of ipilimumab plus nivolumab in metastatic ccRCC informs strategies for optimal immunotherapy sequencing.
A phase 0 trial is seeking to assess the feasibility of aiding anti-cancer cells with cytokines to restore their function.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
Stereotactic body radiotherapy costs less and has shown better safety compared with immunotherapy and tyrosine kinase inhibitors in patients kidney cancer.
Welireg improved quality-adjusted survival time versus Afinitor in advanced renal cell carcinoma, extending progression-free survival and reducing side effects.
A new biomarker, KIM-1, has the potential to show outcomes and response for patients with renal cell carcinoma.
Treatment with casdatifan in combination with cabozantinib produced responses and was safe in patients with pretreated clear cell renal cell carcinoma.
No results found.
Articles from Kidney Cancer UK
No results found.
No results found.